chartexchange

Biohaven Stock Heads for Best Day in 3 Years as FDA Agrees to Review Drug Again

Barron's | Oct 22, 2026 1:29 PM EDT

The Food and Drug Administration agrees to review a New Drug Application for Vyglxia, Biohaven’s experimental spinocerebellar ataxia treatment.

Read original article